CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation.

[1]  G. Stefanzl,et al.  Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML , 2015, Clinical Cancer Research.

[2]  Marianna Zahurak,et al.  Aldehyde Dehydrogenase Expression Drives Human Regulatory T Cell Resistance to Posttransplantation Cyclophosphamide , 2013, Science Translational Medicine.

[3]  Gavin Giovannoni,et al.  Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial , 2013, The Lancet.

[4]  J. Ritz,et al.  Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease , 2013, Science Translational Medicine.

[5]  J. Ritz,et al.  CD25+ Regulatory T CELL-Depleted Donor Lymphocyte Infusion for Relapse After Allogeneic Transplantation – A PHASE 1 Study , 2013 .

[6]  P. Westervelt,et al.  Peripheral-blood stem cells versus bone marrow from unrelated donors. , 2012, The New England journal of medicine.

[7]  S. Steinberg,et al.  Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. , 2012, Blood.

[8]  H. Jim,et al.  A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic cell transplantation , 2012, Haematologica.

[9]  J. Ritz,et al.  Interleukin-2 and regulatory T cells in graft-versus-host disease. , 2011, The New England journal of medicine.

[10]  J. Gershan,et al.  Depletion of CD25⁺ T cells from hematopoietic stem cell grafts increases posttransplantation vaccine-induced immunity to neuroblastoma. , 2011, Blood.

[11]  A. Rudensky,et al.  Regulatory T cells and Foxp3 , 2011, Immunological reviews.

[12]  J. Wagner,et al.  Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. , 2011, Blood.

[13]  D. Miklos,et al.  Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation , 2010, Proceedings of the National Academy of Sciences.

[14]  F. Roudot-thoraval,et al.  CD4+CD25+ Regulatory T Cell Depletion Improves the Graft-Versus-Tumor Effect of Donor Lymphocytes After Allogeneic Hematopoietic Stem Cell Transplantation , 2010, Science Translational Medicine.

[15]  D. Littman,et al.  Plasticity of CD4+ T cell lineage differentiation. , 2009, Immunity.

[16]  G. Koren,et al.  Daclizumab therapy for children with corticosteroid‐resistant acute graft‐vs.‐host disease , 2009, Pediatric transplantation.

[17]  G. Dini,et al.  Daclizumab as useful treatment in refractory acute GVHD: a paediatric experience , 2009, Bone Marrow Transplantation.

[18]  M. Roncarolo,et al.  CD4+ T‐regulatory cells: toward therapy for human diseases , 2008, Immunological reviews.

[19]  J. Wagner,et al.  Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  M. Perales,et al.  Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease , 2007, Bone Marrow Transplantation.

[21]  P. Feugier,et al.  Daclizumab, an efficient treatment for steroid‐refractory acute graft‐versus‐host disease , 2006, British journal of haematology.

[22]  R. Negrin,et al.  Role of naturally arising regulatory T cells in hematopoietic cell transplantation. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  C. Anasetti,et al.  T regulatory cells as an immunotherapy for transplantation , 2006, Expert opinion on biological therapy.

[24]  S. Ziegler,et al.  Cutting Edge: Anti-CD25 Monoclonal Antibody Injection Results in the Functional Inactivation, Not Depletion, of CD4+CD25+ T Regulatory Cells1 , 2006, The Journal of Immunology.

[25]  M. A. Curotto de Lafaille,et al.  Control of homeostatic proliferation by regulatory T cells. , 2005, The Journal of clinical investigation.

[26]  E. Holler,et al.  Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept , 2005, Bone Marrow Transplantation.

[27]  Jiang Zhu,et al.  Alloreactive Memory T Cells Are Responsible for the Persistence of Graft-versus-Host Disease1 , 2005, The Journal of Immunology.

[28]  Harriet Noreen,et al.  Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. , 2004, Blood.

[29]  D. Zahrieh,et al.  Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. , 2004, Blood.

[30]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[31]  R. Storb,et al.  Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[32]  B. Levine,et al.  In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. , 2004, Blood.

[33]  N. Geller,et al.  Improved survival in steroid‐refractory acute graft versus host disease after non‐myeloablative allogeneic transplantation using a daclizumab‐based strategy with comprehensive infection prophylaxis , 2004, British journal of haematology.

[34]  C. Fathman,et al.  CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation , 2003, Nature Medicine.

[35]  Laurence L. George,et al.  The Statistical Analysis of Failure Time Data , 2003, Technometrics.

[36]  M. Steurer,et al.  Increase of regulatory T cells in the peripheral blood of cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  T. Panzarella,et al.  A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. , 2002, Blood.

[38]  C. Fathman,et al.  Donor-type CD4+CD25+ Regulatory T Cells Suppress Lethal Acute Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation , 2002, The Journal of experimental medicine.

[39]  M. Kiehl,et al.  Treatment of steroid refractory acute and chronic graft‐versus‐host disease with daclizumab , 2001, British journal of haematology.

[40]  R Storb,et al.  Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. , 2001, The New England journal of medicine.

[41]  J. Shimizu,et al.  Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. , 1999, Journal of immunology.

[42]  T. Fujita,et al.  Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. , 1999, Cancer research.

[43]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[44]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.

[45]  K. Cleary,et al.  Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. , 2000, Blood.

[46]  K. Sullivan.  Acute and chronic graft-versus-host disease in man. , 1986, International journal of cell cloning.